Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists

Abstract

Disclosed is a method of administration and device for the improved bioavailability of leukotriene receptor antagonists. This method and device involve an alkaline surface pH oral film dosage form designed to deliver leukotriene receptor antagonists, such as Montelukast, to the stomach in an amorphous precipitate suspended in aqueous medium. Also disclosed is a device and method for treating a disease, such as a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having an alkaline surface pH film layer and a safe and effective amount of Montelukast. The device is configured and formulated to predominantly achieve enteral delivery of the Montelukast. The method includes enterally delivering to a human or an animal in need of treatment, a safe and effective amount of Montelukast capable of crossing the blood-brain barrier.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to U.S. application Ser. No. 15 / 940,288, filed Mar. 29, 2018, which claims priority to Provisional Application No. 62 / 478,876, filed Mar. 30, 2017, and which also is a continuation-in-part of U.S. application Ser. No. 15 / 067,309, filed Mar. 11, 2016; and Ser. No. 15 / 299,054, filed Oct. 20, 2016 (now U.S. Pat. No. 9,949,934), respectively, the entire contents of which are hereby incorporated by reference in their entireties.FIELD OF THE DISCLOSURE[0002]This disclosure concerns a formulation and method of treatment and pharmaceutical dosage form for improving the bioavailability of a leukotriene receptor antagonist or leukotriene synthesis inhibitor for the treatment of a disorder.BACKGROUND OF THE DISCLOSURE[0003]As the brain ages, it loses its ability to generate new cells, while existing cells lose functionality, including the ability to prevent inflammatory mediators in the blood from passing through the...

AI Technical Summary

Benefits of technology

The patent is about a new kind of oral film medication that can improve the absorption of a type of medication called leukotriene antagonist inhibitor. This medication is often used to treat allergies and other respiratory illnesses. The new film medication has a pH level that is higher than other commercially available options, which can make it better for the body to absorb the medication. This new form of medication is also easier to dissolve in the mouth, and may be more effective without needing to be swallowed or chewed.

Problems solved by technology

At the same time the aged brain tends to produce higher levels of inflammatory agents such as leukotrienes, and loses some of its ability to counter the effects of inflammatory mediators, resulting in neuroinflammation and cognitive impairment.

Presently, Montelukast sodium is marketed in a tablet form under the name of “Singulair®.” One of the greatest challenges for using MTL in a tablet form is the inconsistent bioavailability.

This has led to relatively slow and inconsistent absorption into the blood stream, with maximum concentrations occurring only after 2-4 hours, thereby limiting its use to chronic applications rather than for rapid acute treatment.

Experimental studies indicate that the major obstacles limiting MTL absorption pertain to its solubility, the rate of dissolution from the tablet platform and the rate of transport / permeation across biological membranes.

However, MTL can only exert its therapeutic effects if it crosses the blood-brain barrier (BBB) and accumulates in the cerebrospinal fluid (CSF) at sufficient concentration levels.

The Surge Dose® product may still be limited by gastric emptying cycles and food effects similar to the Singulair® tablet and chewable.

Images